CT-388
Enith-MACE
Roche · Phase 3 · Not yet recruiting · Enrollment 8200
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Arm 1: Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| Arm 2: Enicepatide | Obesity or overweight | n/r | n/r | n/r | n/r |
Disease Pipeline Tools Obesity
Obesity
Programs, trials, and reported weight change for obesity and overweight.
CT-388
Roche · Phase 3 · Not yet recruiting · Enrollment 8200
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Arm 1: Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| Arm 2: Enicepatide | Obesity or overweight | n/r | n/r | n/r | n/r |